ACL is a leading Australian private provider of pathology services. ACL is one of the largest private hospital pathology businesses nationally1 and in its four established regions of Western Australia, Victoria, South Australia and the Northern Territory, has an equivalent market position in community pathology2 to Sonic Healthcare and Healius. ACL has a growing presence in New South Wales and the Australian Capital Territory3 and has recently expanded into Queensland.

Australian Clinical Labs Overview

Market position ·        One of the largest private hospital pathology businesses nationally4

·        Established position in community pathology5 across WA, VIC, SA and the NT

·        Number three and growing presence in NSW and the ACT6 and growing presence in QLD

ACCs ·        995 ACCs7
Skin cancer clinics ·        30 specialist skin cancer clinics8

·        Diagnosed approximately 15% of all reported melanomas in Australia in 20209

Hospitals ·        Primary pathology provider to two of the three largest private hospital groups

·        Services over 90 hospitals

NATA laboratories ·        86 accredited laboratories10 including four central laboratories
Episodes per annum ·        8.3 million11
Pathologists and Scientists ·        Over 90 pathologists and over 500 scientists
FTE employees ·        2,79412
Key operational characteristics ·        Unified pathology system operating primarily under the ACL brand

·        Efficient unified laboratory network

·        Clinical centres of excellence

·        Digitally enabled platforms

·        Focus on research, innovation and advocacy

·        Clinical governance and training

Sites and Locations

ACL has a national footprint of 995 ACCs and 30 clinics to collect patient samples and operates 86 NATA accredited laboratories across Australia.

ACL Footprint13

Last updated 26/04/21


References

1.Based on information sourced from Medicare Benefits Schedule Item Statistics Report for Category 6 “Pathology Services”, P10 Patient Episode Initiation, and ACL data for the year ending 30 June 2020. Based on ACL’s private hospital segment position in its established states of Western Australia, South Australia, Victoria and the Northern Territory by Patient Episode Initiation.
2.By number of ACCs as at 1 February 2021 excluding 1 SunDoctors ACC. The number of ACCs can be used as an illustrative proxy for community pathology segment position, though is not an accurate reflection of revenue due to various factors including differences in ACC size, medical practice size and location.
3.By number of ACCs as at 1 February 2021 excluding 1 SunDoctors ACC. The number of ACCs can be used as an illustrative proxy for community pathology segment position, though is not an accurate reflection of revenue due to various factors including differences in ACC size, medical practice size and location.
4.Based on information sourced from Medicare Benefits Schedule Item Statistics Report for Category 6 “Pathology Services”, P10 Patient Episode Initiation, and ACL data for the year ending 30 June 2020. Based on ACL’s private hospital segment position in its established states of Western Australia, South Australia, Victoria and the Northern Territory by Patient Episode Initiation.
5.By number of ACCs as at 1 February 2021 excluding 1 SunDoctors ACC. The number of ACCs can be used as an illustrative proxy for community pathology segment position, though is not an accurate reflection of revenue due to various factors including differences in ACC size, medical practice size and location.
6.By number of ACCs as at 1 February 2021 excluding 1 SunDoctors ACC. The number of ACCs can be used as an illustrative proxy for community pathology segment position, though is not an accurate reflection of revenue due to various factors including differences in ACC size, medical practice size and location.
7.As at 1 February 2021.
8.As at 1 February 2021.
9.Includes external referrers. Based on number of melanomas identified as a proportion of total diagnoses published by the Australian Government, Cancer Australia, for the 12 months to 31 December 2020, https://www.canceraustralia.gov.au/affected-cancer/cancer-types/melanoma/melanoma-skin-statistics.
10.As at 1 February 2021, ACL has 86 NATA (National Association of Testing Authorities, Australia) accredited laboratories, or 44 laboratory locations when excluding point of care laboratories.
11.For the 12 months to 31 December 2020. Note, “episode” refers to a pathology service or services which is requested for a single patient, on the same day by one or more practitioners.
12.As at 28 February 2021.
13.ACCs and clinics as at 1 February 2021. As at 1 February 2021, ACL has 86 NATA (National Association of Testing Authorities, Australia) accredited laboratories, or 44 laboratory locations when excluding point of care laboratories. Branch laboratories include two SunDoctors branch laboratories and ACL’s new branch laboratory in Queensland (expected to open in 2021). Specialist laboratories include molecular testing facilities at Clayton Laboratory and environmental testing facilities at Bella Vista, Adelaide Airport and Clayton Laboratories.